Causes and Transmission of Hepatitis C
Question:
Discuss about the Current and Future Disease Burden of Chronic.
Hepatitis C implies inflammation of the liver caused by drugs, viruses, autoimmune diseases, and alcohol. The pathogens (bloodborne) associated with hepatitis C is called HCV. HCV results in severe, lasting liver damage alongside death (potentially). HCV was identified in the year 1989. Most hepatitis C infection (50 to 85%) turns to chronic thereby leading to liver disease. Hepatitis C infection is characteristically mild at initial phases, and it is usually not diagnosed till it has triggered substantial liver damage. The cycle of this illness from infection to significant damage to the liver takes twenty years and more (Abdel-Hamid et al., 2007).
The HCV is a bloodborne virus. The mode of transmission can be injection of drug use via the injection equipment sharing; the reutilization/insufficient medical equipment sterilization (esp. syringes); alongside the unscreened blood and associated products’ transfusion. It can further be sexually transmitted and able to be passed from an infected mother to the baby; nevertheless, these modes remain less common (Nouroz, Shaheen, Mujtaba & Noreen, 2015). The HCV host is the human liver. It enters the host cell via the interactions of a coordinated pathway of sexual co-receptor that are yet to be elucidated entirely.
Human symptomology: The Hepatitis C’s incubations is usually two weeks to six months. After the first infection, nearly 80 percent of the individual don’t display any symptoms. Acutely symptomatic individuals could manifest fever, declined appetite, nausea, fatigue, abdominal pain, vomiting, joint pain, grey-colored faeces, dark urine, and jaundice (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
It is lymphotrophic illness associated with two distinct kinds of arthritis-rheumatoid and intermittent monoarticular/oligoarticular non-destructive one. The former arthritis-like picture, albeit milder, and seldom linked to erosions. The latter affects huge-and medium-sized joints, usually with mixed cryoglobulinemia. HCV could coexist alongside JIA; albeit no pediatric studies evidence (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
The HCV infection leads to immunity. It is bizarrely useful in creating a lasting infection, feasibly mediated by the impaired immune response to the virus infection. It affects immune cells like macrophages, T cells and B cells. HCV core entails immunomodulatory function that suppresses the immune response of the host. This changed function of immune cells triggered by HCV accounts for the inefficient immune response to the virus (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
There is an extremely high HCV prevalence (up to 41% in some studies) in Egypt. The incidence, overall, seems to surge suddenly with age whereby the uppermost rates identified amongst over 40 years. Higher prevalence is also noted in blood donors who are paid alongside family replacement blood donors as opposed to unpaid ones. Higher prevalence is also pointed out among the male blood donors as opposed to the female group (El-Hawary et al., 2007).
The rural-drawn blood donors had a higher prevalence as opposed to urban regions. The village residents showed high prevalence rates of about twenty percent higher than that of the national average. Like blood donors, the village counterparts show higher prevalence among males as opposed to female colleagues. The rate of prevalence in children aged 0 to 19 ranges between 7 and 9.90 percent. People between 20 and 39 years had prevalence rate increased to 27.6 percent from that of children while it more than doubled among the villagers above 40 years (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
Symptoms of Hepatitis C
Among the pregnant women, about 8 percent prevalence rate was reported in Benha and Assuit whereas it was as high as fifteen percent in the Nile Delta rural region. Among the rural school children, the prevalence rate average was approximately 4 percent for children who attend outpatient clinics (Estes, 2015). Among the tourism worker, fire brigade personnel and army recruits recorded higher prevalence.
A lower HCV prevalence was observed among the blood donors after 2001 infection control initiatives as opposed to the prior to 2001. Nonetheless, no clear trend was observed per other subgroups (Kandeel et al., 2017).
The categories including viral hepatitis-, thalassemia-, multi-transfused- schistosomiasis patients, IDUs and patients on hemodialysis are classified as either high risk or direct of HCV exposure. The range of HCV prevalence amongst the acute viral hepatitis patients was between 4.3 and 78.70 percent in studies carried out in rural areas against the urban regions. The viral hepatitis children prevalence rate in 2010 stood at 8.7 percent. The multi-transfused alongside thalassemia groups showed HCV prevalence rate among children to be around 42% and 58% respectively (Ray, Arthur, Carella, Bukh & Thomas, 2000).
The hemodialysis group shows exceptionally high adult and children HCV prevalence. Amongst the schistosomiasis group, the past PAT exposure was identified in two of six studies. Previous PAT campaigns exposure appears to be assumed implicitly given the context of studies and high HCV prevalence crossway studies (Waked et al., 2014). The average prevalence of HCV among schistosomiasis patients stood at 38%, but it has been recently reported by Saba et al. study to be 84 percent for orally treated individuals. The survey of IDUs in Egypt showed an HCV prevalence rate of 63 percent.
No distinguished trend discernible in HCV prevalence distribution in pre- and post- 2001 per subgroups (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
Prevalence of HCV among people at direct/intermediate risk of exposure
Categories include diabetic patients, hospitalized groups, hospital outpatient attendees, STI patients, household contacts of index cases or HCV positive cases, periodontal illness patients, population working in chosen occupation and prisoners (Sievert et al., 2011). Higher prevalence was noted in diabetic children than adults in Egypt than other nations. Patients attending hospital showed higher prevalence ranging between 0 to 72.8 percent.
Prevalence of HCV stood high crossways all groups. Non-Hodgkin’s lymphoma (NHL) patients’ prevalence show about 41 percent whereas it was 39 percent among orthopedic patients and HCC (hepatocellular carcinoma) recorded between 61.0% and 90.30% prevalence rate with the lower rate being observed in urban as opposed to rural. No unique pattern was discernible in HCV prevalence distribution in pre-and post-2001 per special clinical subgroups (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
Some studies have used both general population model alongside direct or high-risk groups in the analysis. In regards to the former model, 26 of 87 general population types of research lacked data gathering year (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013). The outcome of their t-test (paired) recognizes a man variation of 3.10 years (95.0% Confidence Interval: 2.60 to 3.60) between the publication year and data gathering year for researches with each value. The authors applied time lag in the estimation of data gathering year for studies lacking values. In separate univariate linear regression examination of every subgroup, blood donors singly showed a statistically significant alteration in the prevalence of HCV over time (Nafeh, et al., 2000). In multivariate linear regression examination for merged general population subgroups, no proof of a statistically drop in the HCV prevalence was observed over time.
Prevalence Rates of Hepatitis C in Egypt
In the latter model, 25 of 46 direct/ high-risk group studies lacked data gathering year. The outcome of t-test (paired) acknowledged a 3.30 years mean variation (95.0% Confidence Interval: 4.0-2.60) between data collection and publication year. The time lag was applied in estimating data gathering year for researches without values (Miller & Abu-Raddad, 2010). None of proof of a statistically significant drop in incidence of HCV over time per high-risk subgroup as a whole.
Egypt has already launched an HCV treatment programs utilizing direct-acting antivirals (DAAs). 5 conceivable programme scale-up together with sustainability scenarios for the prevention of HCV in Egypt assessment helps determine the future of HCV in case no further strategies are implemented. The analysis showcases that there is a declining trend in the prevalence of Egypt’s HCV. However, from the literature reveals that the HCV prevalence will persist to a substantial degree for decades if Egypt does not control it by interventions (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
The assessment reveals that crossways the five programme scenarios, 1.75M to 5.6M treatments stood subsequently administered by year 2030 (Ayoub & Abu?Raddad, 2017). The reduction in HCV incidence or the yearly quantity of new infections by 2030 varied between 20 to 99.0%. The programme-attached decrease in the rate of occurrence of new infections a susceptible individual a year ranged between eighteen and ninety-nine percent.
The number of averted infection varied between 42,393 and 469,599 and prevalence of chronic infections hit as low as 2.80% to 0.1%. The prevalence increase rate reductions year by year ranged between 7 and 15 percent in 1st ten years of programme in many scenarios. In 2030, the coverage of treatment hovered between 24.90% and 98.80%, and the treatment quantity needed to prevent a single unique infection hovered between 12.10 and 9.50 (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
The projected target for the year 2030 might never be accomplished in the absence of treatment up-scaling to 365,000 a year alongside sustaining it for ten years. To sum up, the DAA scale-up shall have a substantial and instant influence on the incidence of HCV in Egypt. Elimination of HCV prevalence remains feasible by the year 2030 only if Egypt commits adequate resources to programme scale-up alongside sustainability. The treatment of HCV as prevention is a practical and potent approach to prevention (Mohamoud, Mumtaz, Riome, Miller & Abu-Raddad, 2013).
The implication of different scale-up scenarios and sustainability assessment performed by Ayoub & Abu?Raddad (2017) for the HCV-Tasp in Egypt presents a clear picture of HCV prevalence in the coming ten years without new interventions. The forecasted epidemiologic, programming as well as health economics measures illustrate that HCV-TasP remains a compelling and potent prevention intervention which can result in the elimination by the year 2030.
Egypt has the rare opportunity currently to avert 500, 000 new HCV infections and remove HCV and much of HCV’s illness sequelae by the year 2030. This will only be accomplished by scaling-up as well as sustaining Egypt recently launched treatment programme, DAA.
High-Risk Subgroups for Hepatitis C in Egypt
References
Abdel-Hamid, M., El-Daly, M., Molnegren, V., El-Kafrawy, S., Abdel-Latif, S., Esmat, G., … & Widell, A. (2007). Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. Journal of general virology, 88(5), 1526-1531.
Ayoub, H. H., & Abu?Raddad, L. J. (2017). Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. Journal of viral hepatitis, 24(6), 486-495.
El?Akel, W., El?Sayed, M. H., El Kassas, M., El?Serafy, M., Khairy, M., Elsaeed, K., … & Shaker, M. K. (2017). National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. Journal of viral hepatitis, 24(4), 262-267.
Elgharably, A., Gomaa, A. I., Crossey, M. M., Norsworthy, P. J., Waked, I., & Taylor-Robinson, S. D. (2017). Hepatitis C in Egypt–past, present, and future. International journal of general medicine, 10, 1.
El-Hawary, M. A., El-Raziky, M. S., Esmat, G., Soliman, H., Abouzied, A., El-Raziky, M., … & El-Karaksy, H. (2007). Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World Journal of Gastroenterology: WJG, 13(20), 2846.
Estes, C., Abdel?Kareem, M., Abdel?Razek, W., Abdel?Sameea, E., Abuzeid, M., Gomaa, A., … & Waked, I. (2015). Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Alimentary pharmacology & therapeutics, 42(6), 696-706.
Kandeel, A., Genedy, M., El?Refai, S., Funk, A. L., Fontanet, A., & Talaat, M. (2017). The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver International, 37(1), 45-53.
Kouyoumjian, S. P., Chemaitelly, H., & Abu-Raddad, L. J. (2018). Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Scientific reports, 8(1), 1661.
Lehman, E. M., & Wilson, M. L. (2009). Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. Journal of viral hepatitis, 16(9), 650-658.
Miller, F. D., & Abu-Raddad, L. J. (2010). Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proceedings of the National Academy of Sciences, 107(33), 14757-14762.
Mohamoud, Y. A., Mumtaz, G. R., Riome, S., Miller, D., & Abu-Raddad, L. J. (2013). The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infectious diseases, 13(1), 288.
Nafeh, M. A., Medhat, A., Shehata, M., Mikhail, N. N., Swifee, Y., Abdel-Hamid, M., … & Sallam, I. (2000). Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. The American journal of tropical medicine and hygiene, 63(5), 236-241.
Nouroz, F., Shaheen, S., Mujtaba, G., & Noreen, S. (2015). An overview on hepatitis C virus genotypes and its control. Egyptian Journal of Medical Human Genetics, 16(4), 291-298.
Ray, S. C., Arthur, R. R., Carella, A., Bukh, J., & Thomas, D. L. (2000). Genetic epidemiology of hepatitis C virus throughout Egypt. The Journal of infectious diseases, 182(3), 698-707.
Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., AlOmair, A., … & Elshazly, M. (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International, 31(s2), 61-80.
Waked, I., Doss, W., El-Sayed, M. H., Estes, C., Razavi, H., Shiha, G., … & Esmat, G. (2014). The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol, 15(2), 45-52.
Order an Essay Now & Get These Features For Free:
Turnitin Report
Formatting
Title Page
Citation
Outline
